Navigation Links
U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014
Date:9/1/2010

INDIANAPOLIS, Sept. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

"We are pleased with today's ruling from the Court of Appeals regarding Evista's method-of-use patents and believe that the Court fairly applied long-standing patent law principles," said Robert A. Armitage, senior vice president and general counsel for Lilly.  "We remain confident that Evista's method-of-use patents are valid, a conclusion reached by both the District Court and now the Court of Appeals. Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. We will continue to vigorously defend our rights, in order to support the development of the next generation of innovative medicines."

The Court of Appeals also affirmed a prior District Court ruling that held Evista's particle-size patents invalid. The company will review its legal options regarding this aspect of the ruling.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Evista patent litigation. These statements are based on management's current expectations but actual results may differ materially.  There can be no assurance that the company will prevail in any further appeal. Other risk factors that may affect the company's results can be found in the company's latest Form 10-K, filed February 2010, and Form 10-Q, filed July 2010.

Evista® (raloxifene HCl, Lilly)

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
3. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
4. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
5. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
6. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
7. CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures
8. Texas Court Asked to Appoint Receiver for Key Subsidiary of TSX Listed Northstar Healthcare, Inc. (TSX NHC) on Claims of Mismanagement and Breach of Fiduciary Duty
9. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
10. Appellate Court Decides in Favor of Fenwal
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 Endo International plc (NASDAQ: ... May 9, 2017. Members of its senior management team will host ... at 8:30 a.m. ET. The dial-in number to ... International (678) 509-7598, and the passcode is 6086379. Please dial in ... A replay of the call will be available ...
(Date:4/20/2017)... April 20, 2017  Vivify Health, the pioneer and ... been awarded a very significant patent for the advancement ... continual care via digital health.  This landmark patent provides ... and further secures Vivify,s position as the leader in ... was the first company to apply consumer mobile devices, ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers ... study of ActiGraph’s CentrePoint Data Hub in a sample of participants ... clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. The ...
(Date:4/28/2017)... York (PRWEB) , ... April 28, 2017 , ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, ... the hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation ... A Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied ... immediately to IRR programs, the report highlights proven behavioral economics approaches and the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain ... Public Leadership in Neurology Award (PLINA). The couple joins a prestigious list of ... President Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet ...
Breaking Medicine News(10 mins):